Efficacy and Safety of IL-5 Pathway-Targeting Biologics (Mepolizumab, Reslizumab, Benralizumab) in the Management of Hypereosinophilic Syndromes: A Systematic Review and Meta-Analysis. OAIJMR. 2025;5(5):607-626. doi:10.37275/oaijmr.v5i5.780